Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Request metadata listed Merck & Co., Inc., but the filing text is for Schering-Plough).
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Overview: Schering-Plough is a research-based pharmaceutical company operating in Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments. The company is currently in the "Turnaround" phase of a strategic Action Agenda. Financial performance is heavily dependent on the cholesterol franchise (VYTORIN and ZETIA) developed in a joint venture with Merck & Co., Inc., which is accounted for using the equity method.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $2,551 million | $2,369 million |
| Net Income | $372 million | $127 million |
| Net Income Available to Common Shareholders | $350 million | $105 million |
| Diluted EPS | $0.24 | $0.07 |
| Operating Cash Flow | $168 million | $200 million |
| Cash and Cash Equivalents (End of Period) | $2,583 million | $3,912 million |
| Total Debt (Short-term + Long-term) | $3,201 million | $3,677 million (Dec 2005) |
| Equity Income from Cholesterol Joint Venture | $311 million | $220 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% to $2.55 billion, driven by growth in Prescription Pharmaceuticals (up 10%). Key drivers included REMICADE (+26%), NASONEX (+25%), TEMODAR (+25%), and PEG-INTRON (+16%). This growth was partially offset by a 5% unfavorable foreign exchange impact.
- Profitability Surge: Net income available to common shareholders nearly tripled to $350 million. This was primarily due to a 42% increase in equity income from the cholesterol joint venture ($311 million vs. $220 million) and a one-time $22 million benefit from the adoption of SFAS 123R (share-based compensation accounting).
- Expense Increases: Research and Development (R&D) expenses rose 25% to $481 million due to increased headcount, clinical trial costs, and an upfront licensing payment. Selling, General, and Administrative (SG&A) expenses remained flat at $1.086 billion.
- Cash Flow: Operating cash flow decreased to $168 million from $200 million, largely due to timing of payments and changes in working capital (specifically a $251 million increase in accounts receivable). Investing activities consumed $1.785 billion, primarily due to net purchases of short-term investments.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Cholesterol Franchise: Management expects continued growth in the VYTORIN and ZETIA franchise, which is the primary driver of profits. The franchise is projected to cross the 15% threshold of new prescriptions in the U.S. cholesterol market.
- Earnings Seasonality: Earnings in the first half of 2006 are expected to be higher than the second half due to seasonal business patterns, continued high R&D spending, and anticipated unfavorable sales comparisons for the hepatitis franchise in Japan.
- R&D Investment: R&D spending is expected to increase faster than net sales as the company advances its pipeline, including Phase II trials for a Thrombin Receptor Antagonist, Hepatitis Protease Inhibitor, and the HIV drug vicriviroc.
- Infrastructure: The company plans to invest approximately $300 million over the next several years in a new pharmaceutical sciences center.
Risks and Contingencies
- Legal and Regulatory Investigations: The company faces ongoing investigations by the U.S. Attorney's Office for the District of Massachusetts regarding sales and marketing practices. A liability of $500 million has been recorded. There are also investigations into Average Wholesale Price (AWP) practices and a pending Consent Decree with the FDA regarding manufacturing compliance.
- Generic Competition: The company anticipates generic competition for Pravachol and Zocor (cholesterol drugs) and existing products like ELOCON and CIPRO, which could negatively impact sales.
- Regulatory Scrutiny: Increased focus on pharmacovigilance and safety by global health authorities (FDA, EMEA) poses risks of delays, recalls, or sanctions.
- Pseudoephedrine (PSE) Restrictions: New federal and state restrictions on the sale of PSE-containing products (e.g., CLARITIN-D) are expected to continue to adversely affect Consumer Health Care sales.
Investor Verification Checklist
- Joint Venture Dependency: Verify the sustainability of the cholesterol joint venture income ($311 million), which represents a significant portion of total net income.
- Legal Reserves: Confirm the status of the $500 million liability recorded for the Massachusetts investigation and potential additional costs from the FDA Consent Decree.
- Working Capital Trends: Monitor the $251 million increase in accounts receivable and its impact on future operating cash flows.
- R&D Pipeline Progress: Track the success of Phase II trials for key pipeline compounds (Thrombin Receptor Antagonist, Hepatitis Protease Inhibitor) to justify the 25% increase in R&D spend.
- Product Lifecycle: Assess the impact of generic entry for major products (Pravachol, Zocor, ELOCON) on future revenue streams.